{"product_id":"bd-five-forces-analysis","title":"Becton Dickinson Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBecton Dickinson operates in a high-stakes medical devices market where supplier quality, regulatory barriers, and buyer demands shape profitability; competitors and potential substitutes heighten pressure on margins and innovation cycles.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Becton Dickinson’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on specialized medical grade raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBecton Dickinson relies on medical‑grade resins, plastics and specialty alloys that meet FDA and ISO 13485 standards, and only about 8–12 global suppliers per material category hold these certifications, giving suppliers pricing and delivery leverage. Suppliers' leverage raised material costs by an estimated 3–5% for BD in 2024, so BD uses multi‑year contracts and strategic sourcing to lock prices and capacity. BD reported 18% of COGS tied to specialty polymers in 2024, making supplier risk material to margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of specialized electronic component shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs BD adds digital and automated features to diagnostics and medication systems, its reliance on semiconductors rises; global chip shortages in 2021–23 cut production capacity and pushed component lead times to 20–30 weeks, raising supplier leverage and input costs by an estimated 3–5% for medical-device firms in 2024. BD must diversify suppliers and invest in inventory tech (real-time SKU tracking, safety-stock algorithms) to avoid production delays and lost revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching costs for precision manufacturing equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD’s precision manufacturing relies on specialized capital equipment from a few vendors, making supplier switching costly; replacing lines can require $10M–$100M in capex per facility and 6–18 months for revalidation to FDA standards (21 CFR Part 820).\u003c\/p\u003e\n\u003cp\u003eThose costs and validation timelines give equipment suppliers leverage over maintenance, spare parts, and upgrade pricing, affecting BD’s OPEX and time-to-market for new SKUs.\u003c\/p\u003e\n\u003cp\u003eThe relationship is symbiotic but constrained: BD depends on vendor expertise, while suppliers depend on BD’s multi-year contracts (often 3–7 years) for predictable revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and logistics constraints on global sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBecton Dickinson (BD) runs a global supply chain exposed to geopolitical tensions and trade policies that affect key suppliers of plastics, stainless steel, and reagent inputs; in 2024 BD reported ~48% of revenue from outside the US, increasing exposure to regional disruptions.\u003c\/p\u003e\n\u003cp\u003eSuppliers in politically volatile regions or subject to new 2025 environmental rules can raise compliance costs and pass them to BD; analysts estimate supplier-driven input cost inflation of 3–6% in medtech this cycle.\u003c\/p\u003e\n\u003cp\u003eBD mitigates by regionalizing sourcing—shifting capacity to North America and Europe and qualifying multiple suppliers—which cut single-origin dependency and reduced average transit lead times by about 12% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~48% revenue outside US (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated supplier cost inflation 3–6% (2025)\u003c\/li\u003e\n\u003cli\u003eRegionalization cut transit lead times ~12% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation within the medical supply industry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsolidation among specialist medical suppliers has concentrated market share: in 2024 the top 5 suppliers served ~62% of hospital OEM needs, raising their bargaining power vs Becton Dickinson (BD).\u003c\/p\u003e\n\u003cp\u003eLarge vendors now push for better pricing and prioritize big contracts, so BD leverages its $20.7B 2024 revenue scale to secure volume discounts and supply continuity.\u003c\/p\u003e\n\u003cp\u003eBD offsets power by co-developing tech with key suppliers, creating mutual dependencies that lock in terms and reduce disruption risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop-5 suppliers ≈62% market share (2024)\u003c\/li\u003e\n\u003cli\u003eBD revenue $20.7B (FY2024)\u003c\/li\u003e\n\u003cli\u003eJoint R\u0026amp;D deals reduce supply shocks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD’s $20.7B scale trims transit times ~12% but supplier concentration keeps input inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of certified resins, semiconductors and capital equipment hold concentrated power—top‑5 suppliers ~62% share—pushing input cost inflation ~3–6% and adding lead times (20–30 weeks during shortages); BD’s $20.7B 2024 scale, 48% revenue outside US, multi‑year contracts and regional sourcing cut transit times ~12% and reduce but do not eliminate supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD revenue\u003c\/td\u003e\n\u003ctd\u003e$20.7B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue outside US\u003c\/td\u003e\n\u003ctd\u003e~48% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑5 supplier share\u003c\/td\u003e\n\u003ctd\u003e~62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier cost inflation\u003c\/td\u003e\n\u003ctd\u003e3–6% (2025 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip lead times\u003c\/td\u003e\n\u003ctd\u003e20–30 weeks (2021–23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransit time reduction\u003c\/td\u003e\n\u003ctd\u003e~12% (regionalization, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Becton Dickinson, this Porter's Five Forces overview uncovers key competitive drivers, supplier and buyer power, threat of substitutes and entrants, and disruptive forces that shape pricing, profitability, and market defense strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise one-sheet Porter's Five Forces summary for Becton Dickinson—ideal for rapid strategy checks and boardroom-ready slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Becton Dickinsons (BD) US revenue—about 45% in 2024—flows through Group Purchasing Organizations (GPOs) that leverage contracts for 5,000+ hospitals to push lower prices and volume rebates. GPOs aggregate demand to extract single-digit to mid-teens percent discounts, pressuring BD margins; BD counters by tying safety, clinical outcomes, and a broad product portfolio to long-term contracts. Maintaining GPO relationships is critical to secure repeat business and defend a $17.7bn 2024 US addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of healthcare provider systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe wave of hospital and lab M\u0026amp;A has created mega-buyers—US hospital systems’ top 20 groups now control about 40% of admissions (AHA, 2024)—giving them strong price and spec leverage over suppliers like Becton Dickinson.\u003c\/p\u003e\n\u003cp\u003eThese customers standardize procurement and push for integrated solutions that cut ops costs, often seeking multi-year contracts and total-cost-of-ownership metrics.\u003c\/p\u003e\n\u003cp\u003eBD counters with end-to-end systems—for example, automated pharmacy platforms and medication management suites—positioning value in efficiency: BD reported $1.3B in medication-management revenue in FY2024, showing traction beyond unit pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare budget constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic health systems and government-funded programs face tight budgets—global public health spending growth slowed to about 1.9% in 2023—so payers push strict reimbursement and competitive bidding for devices and diagnostics. BD must supply clinical and health-economic evidence showing its products cut total cost of care, e.g., reducing hospital-acquired infections that drive average excess costs of $20,000–$45,000 per case in the US. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow switching costs for commodity medical supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn commodity segments like syringes and collection tubes, switching costs are low, so price sensitivity is high and BD faces margin pressure—global syringe market price declines averaged ~2% annually through 2023–2024 per IHS Markit.\u003c\/p\u003e\n\u003cp\u003eBD leans on brand reliability, supply-chain uptime (99.2% fill-rate in 2024) and safety reputation to retain customers and justify modest price premiums.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow switching costs → higher price sensitivity\u003c\/li\u003e\n\u003cli\u003e~2% annual price decline (2023–24)\u003c\/li\u003e\n\u003cli\u003e99.2% 2024 fill-rate supports loyalty\u003c\/li\u003e\n\u003cli\u003eReputation offsets commodity pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for value based healthcare solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern healthcare buyers now tie payment to outcomes, boosting demand for products that cut stays and complications; value-based care programs covered 34% of US Medicare beneficiaries by 2023, pressuring suppliers.\u003c\/p\u003e\n\u003cp\u003eBD aligns R\u0026amp;D to outcomes—its antimicrobial stewardship and infusion-tech claims reduced device-related infections in trials by up to 25%, turning products into strategic assets for hospitals under risk-based contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e34% Medicare in value programs (2023)\u003c\/li\u003e\n\u003cli\u003eUp to 25% device-infection reduction in BD trials\u003c\/li\u003e\n\u003cli\u003eOutcome-focus raises buyer bargaining power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD faces heavy buyer leverage—GPOs\/top systems drive pricing despite strong fill-rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers wield strong bargaining power: GPOs drive ~45% of BD US revenue (2024) and secure single-digit–mid-teens discounts; top 20 hospital systems account for ~40% of US admissions (AHA, 2024), raising price\/spec leverage. Commodity items see ~2% annual price decline (2023–24); BD defends via 99.2% fill-rate (2024) and outcome-focused products (34% Medicare in value programs, 2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO share of US revenue\u003c\/td\u003e\n\u003ctd\u003e~45% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 20 systems admissions\u003c\/td\u003e\n\u003ctd\u003e~40% (AHA, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill-rate\u003c\/td\u003e\n\u003ctd\u003e99.2% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice decline (commodity)\u003c\/td\u003e\n\u003ctd\u003e~2% p.a. (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare in value programs\u003c\/td\u003e\n\u003ctd\u003e34% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBecton Dickinson Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Becton Dickinson you'll receive immediately after purchase—no placeholders or samples. The document is the fully formatted, professionally written file covering competitive rivalry, supplier and buyer power, threats of entry and substitution, and strategic implications. It’s ready for download and immediate use upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746884727161,"sku":"bd-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bd-five-forces-analysis.png?v=1772192825","url":"https:\/\/matrixbcg.com\/products\/bd-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}